Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD- Naive or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

被引：0

作者：

Husni, M. Elaine ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Merola, Joseph ^{[4
]}

Behrens, Frank

Favalli, Ennio G. ^{[5
,6
,7
]}

McGonagle, Dennis ^{[8
]}

Tillett, William R. ^{[9
]}

Tsuji, Shigeyoshi ^{[10
]}

Ink, Barbara ^{[11
]}

Bajracharya, Rajan ^{[11
]}

Lambert, Jeremy ^{[12
]}

Coarse, Jason ^{[13
]}

Gossec, Laure ^{[14
,15
]}

机构：

[1] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH USA

[2] Swedish Med Center, Providence St Joseph Hlth, Seattle, WA USA

[3] Univ Washington, Sch Med, Seattle, WA USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Newton, MA USA

[5] Goethe Univ, Univ Hosp, Div Rheumatol, Frankfurt, Germany

[6] Fraunhofer Inst Translat Med Pharmacol, Frankfurt, Germany

[7] Univ Milan, ASST Gaetano Pini CTO, Dept Rheumatol, Milan, Italy

[8] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England

[9] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath, England

[10] Nippon Life Hosp, Osaka, Japan

[11] UCB Pharma, Slough, England

[12] UCB Pharma, Irigny, France

[13] UCB Pharma, Morrisville, NY USA

[14] Sorbonne Univ, Paris, France

[15] Hop La Pitie Salpetriere, Paris, France

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

PHASE-3; TRIAL; DOUBLE-BLIND;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0527

引用

页码：1035 / 1038

页数：4

共 50 条

[11] Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
McInnes, Iain
Tillett, William
Mease, Philip
de Vlam, Kurt
Bessette, Louis
Lippe, Ralph
Maniccia, Anna
Zueger, Patrick
Feng, Dai
Kato, Koji
Ostor, Andrew
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[12] IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs
Ostor, Andrew
McInnes, Iain
Tillett, William
Mease, Philip
de Vlam, Kurt
Bessette, Louis
Lippe, Ralph
Maniccia, Anna
Zueger, Patrick
Feng, Dai
Kato, Koji
INTERNAL MEDICINE JOURNAL, 2021, 51 : 38 - 38
[13] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
Gratacos, Jordi
Turkiewicz, Anthony
Dokoupilova, Eva
Gellett, Amanda
Sprabery, Aubrey
Geneus, Vladimir
Constantin, Arnaud
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[14] Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Mease, Philip
Tillett, William
de Wit, Maarten
Gossec, Laure
Husni, M. Elaine
Proft, Fabian
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Lambert, Jeremy
Coates, Laura
Gottlieb, Alice
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4789 - 4792
[15] BIMEKIZUMAB TREATMENT IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
Ostor, Andrew
Ritchlin, Christopher T.
Coates, Laura C.
McInnes, Iain B.
Mease, Philip J.
Merola, Joseph F.
Tanaka, Yoshiya
Asahina, Akihiko
Gossec, Laure
Gottlieb, Alice B.
Thaci, Diamant
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Shende, Vishvesh
Coarse, Jason
Landewe, Robert
INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
[16] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Ritchlin, Christopher
Coates, Laura
McInnes, Iain
Mease, Philip J.
Merola, Joseph
Tanaka, Yoshiya
Asahina, Akihiko
Gossec, Laure
Gottlieb, Alice
Thaci, Diamant
Ink, Barbara
Assudani, Deepak
Bajracharya, Rajan
Shende, Vish
Coarse, Jason
Landewe, Robert
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
[17] BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM A PHASE 3, RANDOMISED STUDY
Tillett, William R.
Merola, Joseph F.
Tanaka, Yoshiya
Favalli, Ennio G.
McGonagle, Dennis
Thaci, Diamant
Walsh, Jessica A.
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Ritchlin, Christopher T.
RHEUMATOLOGY, 2024, 63
[18] Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
Tillett, William R.
Merola, Joseph F.
Tanaka, Yoshiya
Favalli, Ennio G.
Mcgonagle, Dennis
Thaci, Diamant
Walsh, Jessica A.
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Ritchlin, Christopher T.
RHEUMATOLOGY, 2024, 63
[19] BIMEKIZUMAB REDUCED PSORIATIC ARTHRITIS IMPACT IN PATIENTS WITH PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Gossec, Laure
Gladman, Dafna D.
Gisondi, Paolo
de Wit, Maarten
Ogdie, Alexis
Ink, Barbara
Taieb, Vanessa
Lambert, Jeremy
Coates, Laura C.
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[20] Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Walsh, Jessica A.
Merola, Joseph F.
Ritchlin, Christopher T.
Tanaka, Yoshiya
Favalli, Ennio Giulio
McGonagle, Dennis
Thaci, Diamant
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Tillett, William
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1206 - 1209

← 1 2 3 4 5 →